Acute watery diarrhea remains one of the leading causes of morbidity among children under five years of age, particularly in low- and middle-income countries where nutritional deficiencies and infectious exposures are highly prevalent. This study evaluates the effectiveness of folic acid as an adjunct therapeutic intervention in managing acute watery diarrhea in under-five children through a randomized, double-blind, placebo-controlled clinical trial framework. The rationale for folic acid supplementation is grounded in its biological role in epithelial regeneration, immune modulation, and intestinal mucosal repair, which are critical pathways disrupted during diarrheal illness (Field & Stover, 2018; Li et al., 2025).

The study design integrates evidence-based pediatric infectious disease management principles and builds upon prior research demonstrating the role of micronutrient supplementation, including zinc and probiotics, in improving diarrheal outcomes (Imdad et al., 2023; Huang et al., 2021). The trial compares clinical recovery outcomes, stool frequency reduction, duration of illness, and hospitalization rates between folic acid and placebo groups.

Findings are interpreted in the context of existing literature on diarrheal disease burden, gut microbiota interactions, and nutritional immunology (Florez et al., 2020; Collinson et al., 2020). The study further situates its methodological rigor within clinical trial standards and comparative therapeutic frameworks, including surgical and non-surgical intervention research paradigms in critical care medicine (Apampa et al., 2022).

Overall, the research aims to provide an evidence-based evaluation of folic acid as a low-cost, scalable adjunct therapy in pediatric diarrheal management with potential implications for global child health policy.